5-amino-N-cyclopropyl-2,4-difluorobenzamide | 639858-69-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-amino-N-cyclopropyl-2,4-difluorobenzamide
• 英文别名: N-cyclopropyl-5-amino-2,4-difluorobenzamide
• CAS: 639858-69-8
• 化学式: C₁₀H₁₀F₂N₂O
• 分子量: 212.199
• InChiKey: SUZAOKGQWYHSPY-UHFFFAOYSA-N

物化性质

• 沸点：
  304.7±42.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)pyrrolo[2,1-f][1,2,4]triazine 、 5-amino-N-cyclopropyl-2,4-difluorobenzamide 以 乙腈 为溶剂， 以90%的产率得到N-cyclopropyl-2,4-difluoro-5-[[6-(5-methyl-1,3,4-oxadiazol-2-yl)-5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide
  参考文献：
  名称：

  Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors

  摘要：

  Introduction of the 2,4-difluoro-5-(cyclopropylcarbamoyl) phenylamino group at the C-4 position of the pyrrolo[2,1-f] [ 1,2,4] triazine scaffold led to the discovery of a novel sub-series of inhibitors of VEGFR-2 kinase activity. Subsequent SAR studies on the 1,3,5-oxadiazole ring appended to the C-6 position of this new sub-family of pyrrolotriazines resulted in the identifiation of low nanomolar inhibitors of VEGFR-2. Antitumor efficacy was observed with compound 37 against L2987 human lung carcinoma xenografts in athymic mice. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.012
• 作为产物：
  描述：

  2,4-二氟-5-硝基苯甲酸 在 palladium on activated charcoal 氯化亚砜 、 氢气 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， -40.0~25.0 ℃ 、101.33 kPa 条件下， 反应 6.0h， 生成 5-amino-N-cyclopropyl-2,4-difluorobenzamide
  参考文献：
  名称：

  Discovery and Evaluation of N-Cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a Selective and Orally Efficacious Inhibitor of Vascular Endothelial Growth Factor Receptor-2

  摘要：

  Substituted 3-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)-amino) benzamides were identified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity. The enzyme kinetics associated with the VEGFR-2 inhibition of 14 (K-i=49 +/- 9 nM) confirmed that the aminothiazole-based analogues are competitive with ATP. Analogue 14 demonstrated excellent kinase selectivity, favorable pharmacokinetic properties in multiple species, and robust in vivo efficacy in human lung and colon carcinoma xenograft models.

  DOI：

  10.1021/jm060347y

文献信息

• Heterocyclic inhibitors of kinases
  申请人：——

  公开号：US20040077696A1

  公开（公告）日：2004-04-22

  The present invention provides compounds of formula I 1 and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了公式I的化合物 1 以及药用可接受的盐。 公式I化合物抑制生长因子受体如VEGFR-2、FGFR-1的酪氨酸激酶活性，从而使其作为抗癌剂具有用途。公式I化合物还用于治疗其他通过生长因子受体作用的信号转导通路相关的疾病。
• Pyrrolotriazine kinase inhibitors
  申请人：Cai Zhen-wei

  公开号：US20060009454A1

  公开（公告）日：2006-01-12

  The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了式I的化合物及其药用可接受的盐。式I的化合物抑制生长因子受体的酪氨酸激酶活性，如VEGFR-2和FGFR-1，因此使它们可用作抗癌剂。式I的化合物还可用于治疗通过生长因子受体信号传导途径操作的其他疾病。
• NOVEL KINASE INHIBITORS
  申请人：Bhide Rajeev S.

  公开号：US20100041636A1

  公开（公告）日：2010-02-18

  The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供公式（I）的化合物及其药学上可接受的盐。公式（I）的化合物抑制生长因子受体的酪氨酸激酶活性，如VEGFR-2、FGFR-1和IGFR-1，因此使它们有用作抗癌剂。公式（I）的化合物也适用于治疗通过生长因子受体操作的信号转导途径所涉及的其他疾病。
• Kinase inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US08148361B2

  公开（公告）日：2012-04-03

  The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了公式(I)的化合物及其药学上可接受的盐。公式(I)化合物可以抑制生长因子受体如VEGFR-2，FGFR-1和IGFR-1的酪氨酸激酶活性，因此它们可用作抗癌剂。公式(I)化合物也可用于治疗与通过生长因子受体操作的信号转导途径相关的其他疾病。
• WO2008/60907
  申请人：——

  公开号：——

  公开（公告）日：——